Voyager Therapeutics, Inc.
VYGR
$4.46
-$0.42-8.52%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/13/2026
-
Simply Wall St
3/11/2026
-
Tickeron - Stocks
3/11/2026
-
Tickeron - Stocks
3/11/2026
-
Simply Wall St
3/10/2026
-
FierceBiotech.com - Biotech
3/9/2026
-
TipRanks Financial Blog
3/9/2026
-
Zacks Investment Research
3/9/2026
-
MarketBeat
3/9/2026
-
Ticker Report
3/9/2026
-
The Fly
3/9/2026
-
SeekingAlpha.com: All News
3/9/2026
-
Globe Newswire
3/5/2026
-
Zacks Investment Research
3/3/2026
-
Seeking Alpha: Transcripts
3/3/2026
-
SeekingAlpha
3/3/2026
-
MarketBeat
3/2/2026
-
MarketBeat
2/28/2026
-
Tickeron - Technical Analysis
2/27/2026
-
MarketBeat
2/27/2026
-
Tickeron - Stocks
2/26/2026
-
MarketBeat
2/26/2026
-
MarketBeat
2/26/2026
-
MarketBeat
2/26/2026
-
MarketBeat
2/26/2026
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 9, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 259 5340
Address
75 Hayden Avenue
Lexington, MA 02421
Lexington, MA 02421
Country
Year Founded
Business Description
Sector
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and...
more